118 related articles for article (PubMed ID: 27151000)
1. [Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].
Xu Y; Wang J; Yang N; Bai J; Zhang PY; Gu LF; Lei B; Liu J; Wang FX; Huang BQ; Zhang WG; He AL; Cao XM; Chen YX; Ma XR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):405-10. PubMed ID: 27151000
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
3. [A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy].
Yao G; Xie W; Zhou D; He D; He J; Shi J; Luo Y; Zheng W; Wei G; Lin M; Ye X; Cai Z; Huang H
Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):111-7. PubMed ID: 25907840
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].
Wan WL; Wang J; Zhu MX; Zhang W; Ke XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):841-845. PubMed ID: 27752167
[TBL] [Abstract][Full Text] [Related]
5. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
[TBL] [Abstract][Full Text] [Related]
8. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
9. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
10. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
Cui J; Jiang L; Xu B; Bai Y
Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
[TBL] [Abstract][Full Text] [Related]
11. [Influence of L-asaraginase and Pegaspargase on Coagulation Function of Adult Patients with Acute Lymphoblastic Leukemia and Analysis of Related Factors].
Xu LW; Wei XL; Wei YQ; Hao XX; Zhou QJ; Feng R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):30-5. PubMed ID: 26913389
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
13. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Peg-Asparaginase and L-Asparaginase on Coagulation Markers Among Pediatric Patients with Acute Lymphoblastic Leukemia.
Zekavat OR; Safari A; Bordbar MR; Haghpanah S; Zareifar S; Shahriari M; Mohammadzadeh M
Clin Lab; 2022 Feb; 68(2):. PubMed ID: 35142188
[TBL] [Abstract][Full Text] [Related]
15. [Safety of polyethylene glycol conjugated L-asparaginase in patients with acute lymphoblastic leukemia and T cell non-Hodgkin lymphoma].
Cao X; Li J; Zhang W; Duan M; Zhu T; Han B; Zhuang J; Cai H; Chen M; Zhou D
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):177-80. PubMed ID: 25854457
[TBL] [Abstract][Full Text] [Related]
16. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
17. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.
Liu WJ; Wang H; Wang WD; Zhu MY; Liu CC; Wang JH; Lu Y
Sci Rep; 2016 Dec; 6():39463. PubMed ID: 28000713
[TBL] [Abstract][Full Text] [Related]
18. Pegasparaginase: where do we stand?
Zeidan A; Wang ES; Wetzler M
Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697
[TBL] [Abstract][Full Text] [Related]
19. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
20. L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
Alshiekh-Nasany R; Douer D
Acta Haematol; 2016; 135(4):208-10. PubMed ID: 26841296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
